18 research outputs found

    Le dépistage de l'artériopathie oblitérante des membres inférieurs en médecine générale

    No full text
    POITIERS-BU Médecine pharmacie (861942103) / SudocSudocFranceF

    Compact system for in situ laser Doppler velocimetry of blood flow

    Get PDF
    International audienceThis work describes the implementation of a compact system allowing measurement of blood flow velocity using laser Doppler velocimetry in situ. The compact setup uses an optical fiber acting as an emitter and receptor of the signal. The signal is then recovered by a photodiode and processed using a spectrum analyzer. The prototype was successfully tested to measure microbead suspension and whole blood flow velocities in a fluidic chip. Fibers with hemispherical lenses with three different radius of curvature were investigated. This simple yet precise setup would enable the insertion of the fiber via a medical catheter to monitor blood flow velocity in non superficial vessels where previous reported techniques cannot be implemented

    What are differences in characteristics of heart failure patients according to new ESC guidelines derived-LVEF classification?

    No full text
    Congress of the European-Society-of-Cardiology (ESC), Barcelona, SPAIN, AUG 26-30, 2017International audienc

    Pulmonary hypertension in chronic heart failure definitions, advances, and unanswered issues

    No full text
    International audiencePulmonary hypertension (PH) is a common and severe complication of heart failure (HF). Consequently, HF is the leading cause of PH. For many years, specialists have attempted to better understand the pathophysiology of PH in HF, to define its prevalence and its impact on prognosis in order to improve the therapeutic management of these patients. Nowadays, despite the recent guidelines published on the subject, several points remain unclear or debated, and until now, no study has demonstrated the efficacy of any treatment. The aim of this review is to report the evolution of the concepts on post-capillary PH (diagnosis, prevalence, prognosis, and therapeutics). The main issues are raised, focusing especially on the link between structural alterations and haemodynamic abnormalities, to discuss the possible reasons for treatment failures and future potential targets

    Pharmacological treatment of patients with HFrEF: is it really optimized in case of CRT and/or ICD implantation?

    No full text
    Congress of the European-Society-of-Cardiology (ESC) / World Congress of Cardiology, Paris, FRANCE, AUG 31-SEP 04, 2019Poster session 2 n°P1658International audienceBackgroundCardiac resynchronization (CRT) as well as implantable cardiac defibrillator (ICD) in primary prevention should be considered in patients with heart failure and reduced ejection fraction (HFrEF) only when pharmacological treatment has been optimized.Purposewe sought to analyze pharmacological treatments according to the presence or not of CRT-P, CRT-D or ICD in real life HFrEF patients by using a multicenter survey.Methodsthe survey (NCT01956539) was carried out between 2015 and 2018 in 32 hospitals and included 2735 patients with HF who gave their consent during consultation or hospitalization. In this study, we analyzed only outpatients with chronic HFrEF treated for more than 6 months.Resultsamong 1061 patients studied, 138 had CRT-P or CRT-D and 215 had ICD for primary prevention. The main clinical characteristics were: age 65±13 years, ischemic heart disease in, NYHA classes 1, 2, 3 and 4 in 15%, 52%, 23% and 10% cases respectively, systolic blood pressure 115mmHg [IQR 104–129], heart rate 70bpm [IQR 60–80], eGFR 64ml/min/1.73m2 [IQR 46–83]and LVEF was 30% [IQR 24–34]. The table shows the rate of use of evidence-based drugs and the dose for ACEi/ARB and betablockers, according to the presence of ICD or CRT.Conclusionthese results suggest that pharmacological treatment remains poorly optimized in a number of patients with HFrEF who received ICD or CR
    corecore